Bullous Systemic Lupus Erythematosus as a Marker of Treatment-Refractory Systemic Disease: A Case Report

Bullous systemic lupus erythematosus (BSLE) is a rare autoimmune blistering manifestation of systemic lupus erythematosus (SLE), typically regarded as a cutaneous variant with limited prognostic significance. However, its relationship to systemic disease activity and therapeutic response remains incompletely defined. We present a 42-year-old male patient with known SLE and recently diagnosed BSLE, who developed progressive, widespread blistering lesions with mucosal involvement, dyspnea, and constitutional symptoms despite ongoing therapy. Physical examination revealed extensive tense bullae, erosions, and ulcerative plaques involving the extremities, face, and oral mucosa. Laboratory evaluation demonstrated positive autoimmune serologies consistent with SLE, while infectious and thromboembolic etiologies were excluded. Histopathology and direct immunofluorescence confirmed the diagnosis of BSLE. Despite treatment with systemic corticosteroids, hydroxychloroquine, dapsone, and rituximab, the patient experienced continued clinical deterioration requiring hospitalization and escalation of care. This case underscores BSLE as more than a cutaneous manifestation, instead suggesting its role as a marker of aggressive, treatment refractory systemic disease. The persistence and progression of skin lesions despite appropriate immunosuppression paralleled ongoing systemic activity, indicating that refractory cutaneous findings should prompt reassessment of overall disease control rather than be dismissed as isolated dermatologic involvement. Early recognition of this pattern may support timely therapeutic escalation and closer multidisciplinary management, with potential to improve clinical outcomes.